Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study

Abstract Aim Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN‐induced p...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2024-08-01
Σειρά:	Cancer Medicine
Θέματα:	alkaline phosphatase hepatocellular carcinoma lenvatinib monocyte γ‐Glutamyl transpeptidase
Διαθέσιμο Online:	https://doi.org/10.1002/cam4.70065
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!